By Olivia Bennett
Summary: Research into mitochondrial health is opening new avenues for understanding aging and age-related conditions. From NAD+ and mitochondrial signaling to elamipretide’s role in treating Barth syndrome, scientists are exploring ways to help cells maintain energy and function as we age.
Fuel, Signals and Structure: How Mitochondria Research Is Reshaping Aging Science
In September 2025, the FDA approved elamipretide, the first treatment for Barth syndrome – a rare inherited disease in which cells can’t produce enough energy. It was also the first approved drug aimed at mitochondria, the tiny power plants inside our cells. Before that, it spent years in research labs as SS-31.
It treats one rare disease, but it boosted a bigger idea – that healthy mitochondria could matter for how we all age.
Why Mitochondria Matter
Almost everything your body does runs on energy made in these tiny structures. With age, the output tends to drop, and researchers tie that dip to many age-related problems. Scientists are tackling it from three angles: the fuel these power plants burn, the messages they send and what holds them together.
Fuel: The NAD+ Story
Any power plant needs a steady supply line, and for mitochondria it’s a helper molecule. It shuttles energy around the cell, and DNA-repair proteins rely on it too. In 2016, a Mayo Clinic team found that a protein called CD38 gets busier with age, chewing through the molecule as it goes. Older adults had up to 2.5 times more CD38 in their fat tissue than younger ones.
If the supply is draining, can it be topped up? In 2021, a Washington University trial gave 25 women with prediabetes either NMN, a raw material the body uses to build NAD+, or a placebo. After 10 weeks, muscles in the NMN group responded better to insulin. What about the brain? In 2022, doctors in Norway gave nicotinamide riboside, a close cousin of NMN, to people newly diagnosed with Parkinson’s. Brain scans showed higher levels of the molecule.
In 2026, Dutch researchers checked blood from seven groups of people and found that levels barely moved with age. That shifted attention to muscle and brain, where the real changes may happen.
Signals: How Mitochondria Communicate
For a long time, scientists pictured the cell’s power plants as little more than generators. Then, in 2015, a team at USC found that they talk, too – sending out chemical messages that help steer how the body uses energy. One of those messengers is MOTS-c, a short peptide written into their own DNA. In mice, it helped keep blood sugar and metabolism in check.
Structure: Protecting the Plant Itself
This is where SS-31 comes in. The peptide latches onto cardiolipin, a fat in the inner walls of mitochondria that helps them hold their folded shape. Barth syndrome is, at its root, a cardiolipin problem caused by a faulty gene, so a peptide that steadies it was an obvious one to try. Years of lab work later, that idea reached patients.
It All Starts at the Bench
All three lines of research began with experiments on cells and lab animals. Labs that purchase NAD+ or research peptides for such work need tested, properly documented materials. If what’s in the vial doesn’t match the label, the results are worthless.
Bigger human trials are still needed. But the direction is clear: the goal isn’t just adding years to life – it’s adding healthy ones.
Key Points:
- FDA approval: In September 2025, elamipretide became the first FDA-approved treatment for Barth syndrome and the first approved drug targeting mitochondria.
- NAD+ and energy: Researchers are investigating how NAD+ supports cellular energy and DNA repair, and whether compounds such as NMN can improve metabolic function.
- Promising early findings: Small human studies have reported improvements in muscle insulin response with NMN and increased brain NAD+ levels with nicotinamide riboside in people with newly diagnosed Parkinson’s.
- Mitochondrial messaging: Research into MOTS-c, a peptide encoded by mitochondrial DNA, suggests it may help regulate metabolism and blood sugar, based on studies in mice.
- More research needed: Scientists are studying how to protect mitochondrial structure and function, but larger human trials are needed to determine the potential benefits for healthy aging.
Sources
- U.S. FDA press release, September 2025 (fda.gov)
- Camacho-Pereira et al., Cell Metabolism, 2016 (PMID 27304511)
- Yoshino et al., Science, 2021 (doi:10.1126/science.abe9985)
- Brakedal et al., Cell Metabolism, 2022 (PMID 35235774)
- Lee et al., Cell Metabolism, 2015 (doi:10.1016/j.cmet.2015.02.009)
- Tretowicz et al., Nature Metabolism, 2026 (doi:10.1038/s42255-026-01537-5)
This article is for informational purposes only and summarizes published research. It is not medical advice. Research materials mentioned are intended for laboratory use only.
